List of abbreviation: PPAR, peroxisome proliferator-activated receptor; C/EBP, CCAAT/enhancerbinding protein; Cbfa1, core binding factor A1; Osf2, osteoblast-specific factor 2; OSE, osteoblast Previous studies have shown that the activation of PPAR in osteoblasts suppresses osteoblast differentiation and the expression of osteocalcin, one of the osteoblast-specific proteins. However, the mechanism of this inhibition remains unclear. We investigated the effect of PPAR activation on the expression of osteocalcin and analyzed the molecular mechanism. Mouse osteoblastic cell line MC3T3-E1 cells express PPAR, which is transcriptionally active, whereas rat osteosarcoma cell line, ROS 17/2.8 does not. Treatment of MC3T3-E1 osteoblasts and ROS 17/2.8 cells stably transfected with PPAR2 with the PPAR activator, 15-deoxy-û 12,14 prostaglandin J 2 (15d-PGJ 2 ), inhibited the mRNA expression of osteocalcin and Runx2, the latter of which is a key transcription factor in the osteoblastic differentiation. These decreased expressions of osteocalcin and Runx2 were partly explained by the decreased abundance of Runx2 resulting from the suppressed transcription from Runx2 promoter. However, in addition to this indirect effect, the activation of PPAR by 15d-PGJ 2 directly suppressed the Runx2-mediated induction of osteocalcin promoter activity and of the activity of the artificial promoter p6OSE2, which contained six tandem copies of the OSE2 element, the Runx2-binding promoter sequence. This inhibition was mediated by a physical interaction between PPAR and Runx2 and the subsequent repression of the transcriptional activity at the OSE2 sequence.
INTRODUCTION
Mesenchymal cells are able to differentiate into several distinct cell types, including osteoblasts and adipocytes (1) (2) (3) . The mechanisms directing the cells along a particular lineage and the suppression of alternative pathways are not well established although signals derived from the extracellular environment and several key transcription factors have been identified (4) (5) (6) (7) (8) .
PPARs are a family of ligand-activated transcription factors that belong to the nuclear hormone receptor superfamily (9, 10) . PPAR is abundantly expressed in both white and brown adipose tissue and has been known to play a critical role in the regulation of adipocyte differentiation (10) . The transfection of fibroblastic cells with PPAR2 and its subsequent activation with ligand has been shown to be sufficient to initiate adipogenesis (11) . Moreover, determined myoblasts with no inherent adipogenic potential can be induced to transdifferentiate into mature adipocytes by the ectopic (12) . These results suggest that a developmental switch between these highly specialized cell types can be controlled by the expression of key adipogenic transcription factors. A few studies have suggested that PPAR also acts as a molecular switch between the osteogenic and adipogenic pathways. Lecka-Czernik et al. showed that overexpression of PPARγ2 in stromal cell lines resulted in the suppression of Osf2/Runx2, a key transcription factor for osteoblast differentiation (6) , and osteoblast-like biosynthetic activity, while promoting terminal differentiation to adipocyte (13) . Jackson et al. also reported that the treatment of MC3T3-E1 cells with high concentrations of the PPARγ ligands inhibited osteoblast maturation (14) .
These studies suggest insights into the mechanisms underlying aging-related osteoporosis since a decrease in the number and differentiating potential of bone marrow precursors (15) and/or an alteration in the shunting of these cells between the osteoblast and adipocyte lineages (16) were 4 demonstrated in this condition.
One of the osteoblast-specific proteins, known to be suppressed by PPAR activation is osteocalcin (13, 14) . Osteocalcin is a ~6 kilodalton (kDa) γ-carboxylated protein, and comprises up to 15% of the noncollagenous protein of mature bone (17). The expression of osteocalcin is largely restricted to the osteoblasts of bone and the odontoblasts and cementoblasts of teeth (18) . The transcriptional control of osteocalcin gene expression has been extensively studied and two different types of regulation have been identified, namely, hormonal regulation and the tissue-specific regulation (19) . Hormonal regulation is mediated by vitamin D and glucocorticoid through VDRE (20,21) and GRE (22) , respectively, which are both located in the osteocalcin promoter. Recently transcriptional and posttranscriptional stimulation by thyroid hormone has been also reported (23) . Apart from hormone responsive cis-acting elements, two osteoblast-specific elements, OSE1 and OSE2, have been identified in the mouse osteocalcin promoter, and these DNA sequences are known to be involved in the regulation of the tissue-specific expression of the osteocalcin gene (24) . Similar sequences responsible for cell-specific regulation have also been identified in rat osteocalcin promoter (25, 26) .
Of the two identified OSEs, OSE2 binds Runx2 (Cbfa1/AML3/Pebp2.A), a runt related transcription factor, which is essential for osteoblast differentiation. Runx2 is the only osteoblast-specific transactivation factor identified to date (6, 27, 28) and an expression vector containing Runx2 has been shown to increase osteocalcin promoter activity through the OSE2 element (6) . Thus, it is tempting to speculate that Runx2 might be a target of the PPAR mediated suppression of osteocalcin expression observed in previous studies. In this study, we addressed the mechanism through which PPAR 7 Luc and p6OSE2m-Luc plasmids contain six copies of the wild-type or of the mutant OSE2 sequence of the osteocalcin promoter, respectively, followed by a minimal promoter, which directs the expression of luciferase (24) . The pCbfa1-Luc plasmid contains a 135 bp fragment of the mouse Cbfa1/Runx2 promoter from -89 to +46, driving the expression of luciferase and the OSE2 sites within this Cbfa1/Runx2 promoter segment are mutated in the pCbfa1m-Luc reporter (30) . All these reporter plasmids were kindly provided by Dr. Patricia Ducy (Baylor College of Medicine, Houston, TX). PPREx3 TK-Luc containing three copies of the acyl-CoA oxidase PPAR responsive element (PPRE) upstream of the Herpes virus thymidine kinase promoter has been previously described (31) .
GST-PPAR 2 and GST-Runx2 constructs were kindly provided by Dr. Robert Roeder (The Rockefeller University, New York, NY) and Dr. Philip Hinds (Harvard Medical School, Boston, MA), respectively.
Cell Culture: The osteogenic sarcoma cell line ROS 17/2.8 was provided by Dr. Roberto Civitelli (Washington University School of Medicine, St. Louis, MO). ROS 17/2.8 cells have been shown to express several osteoblastic features, including the production of osteocalcin and other matrix proteins (32) . These cells were cultured in DMEM/F12 containing 10% heat-inactivated fetal bovine serum (FBS, BioWhittaker Inc., Walkersville, MD). The mouse MC3T3-E1 osteoblastic cells were derived from spontaneously immortalized calvaria cells and represent immature osteogenic cells (33) .
MC3T3-E1 cells were maintained in DMEM/F12 medium with 10% FBS. During osteoblast maturation studies, MC3T3-E1 cells were cultured in DMEM/F12 medium with 10% FBS supplemented with 50 g/ml ascorbic acid and 10 mM -glycerophosphate. Either 25 M 15d-PGJ 2 or vehicle was added at confluence and with subsequent medium changes (every 3 days). Murine embryonic mesenchymal cells C3H10T1/2 (American Type Culture Collection, Manassas, VA), are 8 pluripotent cells that retain an immature, fibroblast-like appearance under standard tissue culture conditions. C3H10T1/2 cells were grown in Basal Medium of Eagle (BME) containing 10% FBS. The 3T3-L1 preadipocytic cell line was a kind gift from Dr. Jae Bum Kim (Seoul National University, Seoul, Korea). 3T3-L1 cells were maintained in an immature state by culturing in DMEM supplemented with 20% FBS and 2.0 mM glutamine. The following cDNA probes were used : 1.7-kb EcoRI fragment of mouse Runx2(6), 470 bp EcoRI-
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PstI fragment of mouse osteocalcin, 600 bp XbaI-HindIII fragment of PPAR2, and 1.9 kb BamHI fragment of rat -actin. The abundance of mRNA was quantitated from digitized autoradiographic images using SigmaScan (SPSS Science, Chicago, IL).
RT-PCR: First-strand cDNA was synthesized from 2 g of total RNA using a Reverse Transcription GST Pull-down Analyses: GST fusion proteins were induced in E. coli BL21 for 3 h at 25°C by the addition of isopropyl-1-thio-< -D-galactopyranoside (100 µM final concentration) to a 100-ml bacterial culture (A 600 0.5). After induction, bacteria were pelleted for 20 min at 3000 × g and resuspended in 20 ml of ice-cold binding buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1%
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Nonidet P-40, 0.1 mM PMSF, 1 mM EDTA). Bacteria were lysed by freeze-thawing for 5 min in liquid nitrogen followed by thawing for 10 min at 37 ¶C. The lysis procedure was repeated three times.
The freeze-thawed bacteria were then subjected at 4 ¶C to three 10 s rounds of sonication (7 µ amplitude), and the bacterial debris was pelleted by centrifugation at 15,000 × g for 30 min at 4 °C. Supernatants were stored frozen at -20 ¶C in 100-µl aliquots until needed. Free GST lysates were prepared in a similar manner from E. coli BL21 transformed with a pGEX-3 vector. Free GST and GST fusion proteins were purified on glutathione-Sepharose 4B (Amersham Int., Buckinghamshire, UK) according to the manufacturer's recommendations and dialyzed against binding buffer.
For GST pull-down assays, equal amounts of purified recombinant GST or the GST-fusion proteins were immobilized to glutathione-sepharose beads (Amersham Int., Buckinghamshire, UK) and washed four times with 1 ml of wash buffer (20 mM Tris HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.1% NP-40, 1 mM NaF, 2 g/ml aprotinin, 0.1 mM PMSF) at 4 °C. [
S]-labeled PPAR2 and
Runx2 were synthesized in rabbit reticulocyte lysate by coupled in vitro transcription and translation (TNT T7-coupled reticulocyte lysates system; Promega, Madison, WI) and added to immobilized GST or GST-fusion proteins and incubated for 2 h. After binding, proteins bound to the beads were eluted with elution buffer (10 mM reduced glutathione, 20 mM Tris-HCl (pH 7.5), 0.1 mM PMSF, 0.1% NP-40, 2 g/mL aprotinin) and the samples were separated by SDS-polyacrylamide gel and analyzed by autoradiography.
Immunoprecipitations: MC3T3-E1 cells were lysed in 50 mM of Tris-HCl pH 7.5, 150 mM NaCl, (Fig. 1B) .
PPAR activators inhibit osteocalcin gene expression in rodent osteoblasts
The possibility that PPARγ activators inhibit osteocalcin expression was investigated. ROS 17/2. (Fig. 2B ). This increment, however, was obliterated in the presence of 15d-PGJ 2 (Fig. 2B) . These data support the notion that PPAR activated by 15d-PGJ 2 inhibits the expression of osteocalcin. Since Runx2 is a key transcription factor in the regulation of osteocalcin expression, we investigated the effect of activated PPAR on the expressions of Runx2 in ROS 17/2.8 and MC3T3-E1 cells. As shown in Fig. 2A and 2B, Runx2 mRNA levels were reduced when PPAR was activated, in parallel with the changes observed in osteocalcin mRNA levels. To further confirm the role of PPAR activation on the expression of Runx2, we analyzed the luciferase activity in cells transfected with pCbfa1-Luc, which encompassed the -89/+46 segment of the Runx2 promoter, harboring three conserved OSE2 consensus elements (30) . Transient transfection of pCbfa1-Luc in ROS 17/2.8 cells resulted in constitutive reporter activity, and this activity was reduced in cells cotransfected with the PPARγ2 construct in the presence of 15d-PGJ 2 (Fig. 3A) .
However, cotransfection of PPAR2 construct and treatment with 15d-PGJ 2 failed to suppress the luciferase activity in cells transfected with pCbfa1m-Luc, which carries mutations in all three OSE elements (Fig. 3A) . Likewise, constitutive Runx2 promoter activity in MC3T3-E1 cells was decreased by 15d-PGJ 2 treatment, whereas introducing mutations to all three OSE2 sites resulted in lower reporter activity, which was not repressed by 15d-PGJ 2 (Fig. 3B) . Taken together, these results indicate that the activation of PPAR in osteoblasts results in the suppression of osteocalcin expression, which could be attributed to the decreased transcription and expression of Runx2.
Since Runx2 governs the transcription of osteocalcin, we assessed the effect of PPAR activator on transcription from the osteocalcin promoter in the Runx2-expressing osteoblastic (ROS 17/2.8 and MC3T3-E1) and the mesenchymal (C3H10T1/2) cell line that does not express Runx2 (6) . Transient transfection of -1.3 OG2-Luc, which carries one binding site for Runx2 (24) resulted in constitutive reporter activity in ROS 17/2.8 cells and this transcription was decreased by cotransfection of the PPARγ2 construct in the presence of 15d-PGJ 2 (Fig. 4A) . The same pattern of suppression of OG2
promoter activity was observed when we treated MC3T3-E1 cells with 15d-PGJ 2 (Fig. 4B) . In contrast, 15d-PGJ 2 failed to suppress OG2 promoter activity in C3H10T1/2 cells, a mesenchymal cell line that does not express Runx2 (6) . In these cells, the transfection of -1.3 OG2-Luc showed only a basal level of transactivation, and no effect of 15d-PGJ 2 was observed (Fig. 4C , left 2 columns). However, cotransfection of Runx2 enhanced transcription from the OG2 promoter, and this induction was inhibited by treatment with 15d-PGJ 2 (Fig. 4C, right 2 columns) . These results suggest that the expression of Runx2 is necessary for the inhibitory effect of PPARγ activation. To determine whether other PPAR activators also suppress OG2 promoter activity in C3H10T1/2 cells, we cotransfected the cells with Runx2 and OG2 promoter and added a number of PPAR activators, troglitazone, ciglitazone, and 15d-PGJ 2 , and also fenofibrate, a PPAR. activator. As shown in Fig. 4D , the OG2 promoter activity was suppressed by treatment of other PPAR activators as well, whereas PPAR.
activator fenofibrate showed minimal suppression. This result confirmed the notion that the suppression of OG2 promoter activity by 15d-PGJ 2 resulted from the activation of PPAR.
PPAR decreases the transcriptional activity of Runx2
Murine OSE2 is a cis-acting element in the OG2 promoter that specifically binds Runx2, which is particularly critical for the transcriptional activity of osteocalcin (37) . To confirm that the inhibition of Runx2 activity is essential in the suppression of osteocalcin by PPAR, we examined the role of this sequence in PPARγ -mediated repression. We used an artificial promoter reporter plasmid, p6OSE2-Luc, in which luciferase expression is controlled by six tandem copies of the OSE2 element (24) . In ROS 17/2.8 cells, this promoter showed a high level of transcription, which was inhibited by cotransfection of the PPAR2 construct in the presence of 15d-PGJ 2 (Fig. 5A) . Likewise, exposure of MC3T3-E1 cells to 15d-PGJ 2 suppressed the promoter activity (Fig. 5B) . However, the suppressive effects of 15d-PGJ 2 were partially blocked by overexpressing a dominant negative form of PPAR, confirming the role of PPAR in mediating the inhibitory effects of 15d-PGJ 2 (Fig. 5B) . We also tested the transcription from the p6OSE2m-Luc, in which Cbfa1-binding site is mutated to prevent Cbfa1 binding. As shown in Fig. 5 , the mutated promoter markedly decreased reporter activity in both ROS 17/2.8 ( Fig. 5A ) and MC3T3-E1 cells (Fig. 5B ) and abolished 15d-PGJ 2 -mediated repression.
Together, these results strongly suggest that PPAR activation suppresses the transactivation of osteocalcin promoter by directly affecting the Runx2 binding to the OSE2 element in OG2 promoter.
As has been noted for -1.3 OG2-Luc plasmids in C3H10T1/2 cells, transfection of p6OSE2-Luc resulted in only a low level of luciferase activity in C3H10T1/2 cells in the absence of Runx2 (Fig.   5C ). Cotransfection of the Runx2 expression vector (pCMV-Osf2), however, enhanced transcription in a dose-dependent manner (Fig. 5C) . Treatment of the cells with 15d-PGJ 2 in this setting inhibited Runx2-dependent transcription (Fig. 5D) . Mutation of the OSE2 sites in the p6OSE2m-Luc plasmid abolished the induction of transcription by Runx2 as well as PPARγ-mediated repression (Fig. 5D ).
These findings further confirm that the PPAR-mediated repression of osteocalcin promoter activity depends on the expression of Runx2 as well as the presence of an intact OSE2 site, the Runx2-binding sequence in osteocalcin promoter.
PPAR physically associates with Runx2 and prevents the binding of Runx2 to OSE2
To examine whether activation of PPAR prevents Runx2 from binding to the OSE2-binding sequence, we evaluated the binding of endogenous Runx2 in MC3T3-E1 cells to the OSE2 DNA sequence using gel shift assays. As shown in Fig. 6 , we detected a Runx2-DNA complex in MC3T3-E1 cell lysates (lanes 1 and 5), which could be supershifted using a Runx2 antibody (lane 6). However, when we treated these cells with 15d-PGJ 2 , Runx2 complex formation decreased in a dose-dependent manner (lanes 2-4). This complex was not present in C3H10T1/2 cells that lacked Runx2 expression (lane 7).
To determine the mechanism of the suppression of Runx2 binding to OSE2 by activated PPAR, we examined the possibility of a direct interaction between PPAR and the OSE2 element in the osteocalcin promoter. A gel shift assay by incubating in vitro translated PPAR and RXR heterodimer with radiolabeled OSE2 probes was performed. As shown in Fig. 7 , we were unable to detect any binding of the PPAR-RXR. heterodimer to OSE2 (lane 4). This result indicates that the suppression of Runx2-stimulated OG2 activity by PPAR is not derived from the competition between Runx2 and PPAR for binding to the OSE2 site.
We therefore examined the possibility of physical interaction between PPAR and Runx2 thereby sequestering Runx2 and preventing it from binding to OSE2. First, we assayed directly the protein interactions in vitro, using GST-PPAR2 and in vitro translated Runx2 labeled with [ 35 S]-methionine.
[ 35 S]-labeled Runx2 associates with GST-PPAR2 but not with GST alone (Fig. 8A, left panel) .
Conversely, [
35 S]-labeled PPAR2 showed robust interaction with Runx2 (Fig. 8A, right panel) .
To further evaluate the ability of endogenous PPAR to interact with endogenous Runx2 in vivo, we down Runx2 (Fig. 8B, left panel) . We were also able to find that immunoprecipitation of Runx2 or PPAR coprecipitated PPAR (Fig 8B, right panel) . These results suggest that physical interaction between PPAR and Runx2 perturbs the binding of Runx2 to the OSE2 element, leading to a decrease in the transactivation of the osteocalcin promoter. 
DISCUSSION
This study demonstrates that the mouse osteoblastic cell line MC3T3-E1 expresses functionally active PPAR, and that the activation of PPAR down-regulates Runx2-mediated osteocalcin expression.
We found that Runx2, a transcription factor essential for osteoblast differentiation, is a target of inhibition by PPAR. PPAR activation not only inhibited the transcription and the abundance of Runx2 but also suppressed the transcriptional activity of Runx2, which was mediated by a physical interaction between Runx2 and PPAR. These results provide a mechanistic basis for the inhibition of osteoblast differentiation and osteoblast-gene expression by key molecules in the adipogenic differentiation pathways.
We found that mouse calvarial osteoblastic MC3T3-E1 cells express PPAR, whereas the rat osteosarcoma cell line ROS 17/2.8 does not. Moreover, the PPAR expressed in MC3T3-E1 cells could transactivate the PPAR responsive element, suggesting a functional role of this nuclear receptor in osteoblasts. Of the two PPAR isoforms, only PPAR1 was detectable by RT-PCR, confirming the result of Jackson et al. (14) Absence of PPAR expression in ROS 17/2.8 cells has also been reported previously, whereas significant levels of aP2, a late adipocytic marker, were observed in this cell line (38) . In light of the fact that MC3T3-E1 cells represent immature osteoblasts or preosteoblasts, whereas ROS 17/2.8 cells are osteosarcoma cell lines, these results suggest that PPAR has a role in the early stage of osteoblast differentiation, as a developmental switch from their mesenchymal progenitors.
As a key transcription factor of adipogenic differentiation, the effect of PPAR activation on the reciprocal inhibition of osteogenic differentiation and on the suppression of osteoblast specific gene expression has been demonstrated in previous studies (13, 14) . However, the mechanism of this 21
inhibition has yet to be characterized. Since Runx2 plays an essential role in osteoblast differentiation and in the expression of osteoblast-specific genes, it would be prudent to consider this molecule as a target of PPAR-mediated inhibition. Runx2, also called PEP2. or AML3, is a member of the runt family of transcription factors and has a runt DNA-binding domain (39) . The evidence presented in this report raises clinical issues regarding ageing-related osteoporosis.
Previous studies have shown that increases in the number of adipocytes at the expense of a decrease in the number and differentiation potential of osteoblast progenitors lead to suppression of bone formation rate in ageing related osteoporosis (47) (48) (49) . Moreover, it has been recently shown that the adipose tissue PPAR mRNA level is higher in middle-aged men than in younger individuals (50) . If a similar phenomenon is observed in the bone marrow compartment of aged men, PPAR would be one of the target molecules of intervention in ageing-related osteoporosis. Additional studies will be antibody.
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